Celcuity Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biopharmaceutical company developing targeted therapies for cancer patients using its proprietary CELsignia platform to identify those most likely to benefit from specific treatments. The platform analyzes live tumor cells to measure signaling pathway activity, enabling precision oncology by matching patients to therapies based on tumor biology rather than traditional biomarkers. Core offerings include the CELsignia test service, which provides diagnostic signaling profiles for breast, lung, and other solid tumors; and its lead product candidate, gedatolisib, a pan-PI3K/mTOR inhibitor in Phase 1b/2 trials for hormone receptor-positive, HER2-negative breast cancer in combination with palbociclib and fulvestrant, as well as for other solid tumors. The company operates in the United States, with headquarters in Minneapolis, Minnesota, where it was founded in 2012. Recent developments include positive interim data from the VIKTORIA-1 Phase 2 trial of gedatolisib in November 2024, demonstrating significant progression-free survival benefits; expansion of the CELsignia platform to additional cancer indications; and ongoing collaborations with academic institutions and pharmaceutical partners for companion diagnostic development.
Celcuity: Selloff On Yesterday's Data Unwarranted - Buy Rating Upheld
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy Transcript
What's Going On With Celcuity Stock On Tuesday?
Celcuity plunges after experimental breast cancer treatment data disappoints
Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
Celcuity To Participate in Upcoming Investor Conferences
Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst
Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
Celcuity Q1 Earnings Call Highlights
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
Why Is Celcuity Stock Rallying Today?
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Celcuity: Best-In-Class Potential With 2-3x Upside If Mutant Data Delivers
Why Celcuity Stock Popped on Monday
Nisa Investment Advisors LLC Decreases Stock Holdings in Celcuity, Inc. $CELC